Limits...
Telemonitoring in chronic heart failure: a systematic review.

Giamouzis G, Mastrogiannis D, Koutrakis K, Karayannis G, Parisis C, Rountas C, Adreanides E, Dafoulas GE, Stafylas PC, Skoularigis J, Giacomelli S, Olivari Z, Triposkiadis F - Cardiol Res Pract (2012)

Bottom Line: Heart failure (HF) is a growing epidemic with the annual number of hospitalizations constantly increasing over the last decades for HF as a primary or secondary diagnosis.Despite the emergence of novel therapeutic approached that can prolong life and shorten hospital stay, HF patients will be needing rehospitalization and will often have a poor prognosis.Telemonitoring is a novel diagnostic modality that has been suggested to be beneficial for HF patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Larissa University Hospital, P.O. Box 1425, 41110 Larissa, Greece.

ABSTRACT
Heart failure (HF) is a growing epidemic with the annual number of hospitalizations constantly increasing over the last decades for HF as a primary or secondary diagnosis. Despite the emergence of novel therapeutic approached that can prolong life and shorten hospital stay, HF patients will be needing rehospitalization and will often have a poor prognosis. Telemonitoring is a novel diagnostic modality that has been suggested to be beneficial for HF patients. Telemonitoring is viewed as a means of recording physiological data, such as body weight, heart rate, arterial blood pressure, and electrocardiogram recordings, by portable devices and transmitting these data remotely (via a telephone line, a mobile phone or a computer) to a server where they can be stored, reviewed and analyzed by the research team. In this systematic review of all randomized clinical trials evaluating telemonitoring in chronic HF, we aim to assess whether telemonitoring provides any substantial benefit in this patient population.

No MeSH data available.


Related in: MedlinePlus

Flowchart of study search.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3375160&req=5

fig1: Flowchart of study search.

Mentions: We searched in Medline, SpringerLink, Scopus, Cinahl, and Embase for trials that examined efficacy and efficiency of telemonitoring modalities in chronic HF patients. Keywords used in the search included: home care, telemedicine, telemetry, telemonitoring and telehealth combined with chronic heart failure. This yielded 3378, 322, 288, 130, and 48 papers respectively. The search lasted for two months and ended in November 2011. Two of the researchers read all available titles and abstracts and eliminated duplicate articles. Only randomized controlled trials were included that had a follow-up period of at least six months, clearly stated a means of telemonitoring, and were conducted in the previous ten years. We excluded feasibility or pilot studies which primarily report preliminary findings of ongoing trials, usually, in a small number of patients. Table 1 summarizes inclusion and exclusion criteria. In Figure 1, the selection process is depicted.


Telemonitoring in chronic heart failure: a systematic review.

Giamouzis G, Mastrogiannis D, Koutrakis K, Karayannis G, Parisis C, Rountas C, Adreanides E, Dafoulas GE, Stafylas PC, Skoularigis J, Giacomelli S, Olivari Z, Triposkiadis F - Cardiol Res Pract (2012)

Flowchart of study search.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3375160&req=5

fig1: Flowchart of study search.
Mentions: We searched in Medline, SpringerLink, Scopus, Cinahl, and Embase for trials that examined efficacy and efficiency of telemonitoring modalities in chronic HF patients. Keywords used in the search included: home care, telemedicine, telemetry, telemonitoring and telehealth combined with chronic heart failure. This yielded 3378, 322, 288, 130, and 48 papers respectively. The search lasted for two months and ended in November 2011. Two of the researchers read all available titles and abstracts and eliminated duplicate articles. Only randomized controlled trials were included that had a follow-up period of at least six months, clearly stated a means of telemonitoring, and were conducted in the previous ten years. We excluded feasibility or pilot studies which primarily report preliminary findings of ongoing trials, usually, in a small number of patients. Table 1 summarizes inclusion and exclusion criteria. In Figure 1, the selection process is depicted.

Bottom Line: Heart failure (HF) is a growing epidemic with the annual number of hospitalizations constantly increasing over the last decades for HF as a primary or secondary diagnosis.Despite the emergence of novel therapeutic approached that can prolong life and shorten hospital stay, HF patients will be needing rehospitalization and will often have a poor prognosis.Telemonitoring is a novel diagnostic modality that has been suggested to be beneficial for HF patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Larissa University Hospital, P.O. Box 1425, 41110 Larissa, Greece.

ABSTRACT
Heart failure (HF) is a growing epidemic with the annual number of hospitalizations constantly increasing over the last decades for HF as a primary or secondary diagnosis. Despite the emergence of novel therapeutic approached that can prolong life and shorten hospital stay, HF patients will be needing rehospitalization and will often have a poor prognosis. Telemonitoring is a novel diagnostic modality that has been suggested to be beneficial for HF patients. Telemonitoring is viewed as a means of recording physiological data, such as body weight, heart rate, arterial blood pressure, and electrocardiogram recordings, by portable devices and transmitting these data remotely (via a telephone line, a mobile phone or a computer) to a server where they can be stored, reviewed and analyzed by the research team. In this systematic review of all randomized clinical trials evaluating telemonitoring in chronic HF, we aim to assess whether telemonitoring provides any substantial benefit in this patient population.

No MeSH data available.


Related in: MedlinePlus